Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort.

IF 1.5 4区 医学 Q3 UROLOGY & NEPHROLOGY Urology Journal Pub Date : 2024-10-12 DOI:10.22037/uj.v21i.8055
Taha Cetin, Serdar Celik, Sinan Sozen, Haluk Ozen, Bulent Akdogan, Guven Aslan, Sumer Baltaci, Evren Suer, Yıldırım Bayazit, Volkan Izol, Talha Muezzinoglu, Fatih Gokalp, Ilker Tinay
{"title":"Oncological Outcomes of Chromophobe Versus Clear Cell Renal Cell Carcinoma: Results from A Contemporary Turkish Patient Cohort.","authors":"Taha Cetin, Serdar Celik, Sinan Sozen, Haluk Ozen, Bulent Akdogan, Guven Aslan, Sumer Baltaci, Evren Suer, Yıldırım Bayazit, Volkan Izol, Talha Muezzinoglu, Fatih Gokalp, Ilker Tinay","doi":"10.22037/uj.v21i.8055","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications.</p><p><strong>Materials and methods: </strong>Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype.</p><p><strong>Results: </strong>Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM.</p><p><strong>Conclusion: </strong>chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population.</p>","PeriodicalId":23416,"journal":{"name":"Urology Journal","volume":" ","pages":"320-324"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.22037/uj.v21i.8055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To compare the oncological outcomes of clear cell RCC (ccRCC), which is common in renal cell carcinomas (RCC), and chromophobic RCC (chRCC), which is less common, and to define the factors affecting survival in the Turkish patient population for both RCC subclassifications.

Materials and methods: Patients with a pathologically confirmed RCC diagnosis after radical or partial nephrectomy in the Turkish Urooncology Association (TUOA), Urological Cancers Database-Kidney (UroCaD-K), were retrospectively reviewed. Patients with ccRCC and chRCC were included in the study. Primary outcomes of this study are recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) for each histological subtype.

Results: Data from 5300 patients in the TUOA UroCaD-K are reviewed and a total of 2560 patients (2225 in the ccRCC group and 335 in the chRCC group) are included in the final analysis. In the comparison of the groups, tumor size was greater both radiologically and pathologically in chRCC (p=0.019 vs 0.002 respectively). Recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival (CSS) rates are worse in ccRCC subgroup. In the evaluation of risk factors; pathological stage, local invasion and Fuhrmann grade were found to be significant for recurrence in ccRCC. Age, body mass index and pathological stage were the risk factors affecting overall mortality (OM). Pathological tumor size was an independent risk factor for recurrence in chRCC, while age was analyzed as the only parameter affecting OM.

Conclusion: chRCC oncological data and OS, CSS and RFS rates were found to be better than ccRCC in the Turkish patient population.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
嗜铬细胞肾细胞癌与透明细胞肾细胞癌的肿瘤学结果:当代土耳其患者队列的结果。
目的:比较肾细胞癌(RCC)中常见的透明细胞RCC(ccRCC)和较少见的疏色细胞RCC(chRCC)的肿瘤治疗效果,并确定影响土耳其RCC亚分类患者生存的因素:对土耳其泌尿肿瘤协会(TUOA)泌尿肿瘤数据库-肾(UroCaD-K)中根治性或部分肾切除术后病理确诊为RCC的患者进行回顾性研究。研究对象包括ccRCC和chRCC患者。本研究的主要结果是每种组织学亚型的无复发生存率(RFS)、总生存率(OS)和癌症特异性生存率(CSS):结果:研究回顾了TUOA UroCaD-K中5300名患者的数据,共有2560名患者(ccRCC组2225人,chRCC组335人)被纳入最终分析。在两组患者的比较中,ccRCC患者的肿瘤大小在放射学和病理学上都更大(P=0.019 vs 0.002)。ccRCC亚组的无复发生存率(RFS)、总生存率(OS)和癌症特异性生存率(CSS)更低。在对风险因素进行评估时,发现病理分期、局部浸润和 Fuhrmann 分级对 ccRCC 的复发有显著影响。年龄、体重指数和病理分期是影响总死亡率(OM)的风险因素。病理肿瘤大小是chRCC复发的独立风险因素,而年龄是唯一影响OM的参数。结论:在土耳其患者群体中,chRCC的肿瘤学数据以及OS、CSS和RFS率均优于ccRCC。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Urology Journal
Urology Journal UROLOGY & NEPHROLOGY-
CiteScore
2.60
自引率
6.70%
发文量
44
审稿时长
6-12 weeks
期刊介绍: As the official journal of the Urology and Nephrology Research Center (UNRC) and the Iranian Urological Association (IUA), Urology Journal is a comprehensive digest of useful information on modern urology. Emphasis is on practical information that reflects the latest diagnostic and treatment techniques. Our objectives are to provide an exceptional source of current and clinically relevant research in the discipline of urology, to reflect the scientific work and progress of our colleagues, and to present the articles in a logical, timely, and concise format that meets the diverse needs of today’s urologist. Urology Journal publishes manuscripts on urology and kidney transplantation, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. Accordingly, original articles, case reports, and letters to editor are encouraged.
期刊最新文献
The Comparative Study on the Application Value of Transperineal Prostate Combined Biopsy and Transrectal Prostate Systematic Biopsy in Diagnosing Prostate Cancer in Patients with Different PSA Zones. Comparison of Transurethral Resection of the Prostate (TURP) with 0.5-cm Tissue Preservation Proximal to the Verumontanum and Standard TURP in terms of Postoperative Ejaculation Disorders. Mini-Incision Graft Removal in a Kidney Donor with Duplicated Inferior Vena Cava and Vein Reconstruction Using the Recipient's Great Saphenous Vein. Time to Reach Stone-free Status in Children Undergoing Retrograde Intrarenal Surgery. Effect of 3D Modeling of S-fusion software on Positive surgical Margins in Patients who Underwent Radical Retropubic Prostatectomy: A Randomized Prospective Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1